The GO-DACT protocol: A multicentre, randomized, double-blind, parallel-group study to compare the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy, in improving dactylitis and enthesitis, in MTX-naïve psoriatic arthritis patients

Elsa Vieira de-Sousa, H. Canhão, P. Alves, A. M. Rodrigues, F. Teixeira, J. Tavares-Costa, A. Bernardo, S. Pimenta, F. Pimentel-Santos, J. L. Gomes, R. Aguiar, T. Videira, P. Pinto, C. Catita, H. Santos, G. Sequeira, C. Ribeiro, L. Teixeira, P. Ávila-Ribeiro, F. M. MartinsR. M. Ribeiro, J. E. Fonseca

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)
8 Downloads (Pure)

Abstract

The GO-DACT is an investigator-initiated, multicentric randomized placebo-controlled double-blinded trial, that assesses dactylitis as primary endpoint. Psoriatic arthritis patients naïve to methotrexate and biologic disease modifying anti-rheumatic drugs, with at least one active dactylitis, were assigned to golimumab in combination with methotrexate or placebo in combination with methotrexate, for 24 weeks. Both clinical (dactylitis severity score and the Leeds dactylitis index) and imaging (high resolution magnetic resonance imaging), among others, were assessed as outcomes. The main objective of GO-DACT is to provide evidence to improve the treatment algorithm and care of psoria - tic arthritis patients with active dactylitis. In this manuscript we describe the GO-DACT protocol and general concepts of the methodology of this trial.

Original languageEnglish
Pages (from-to)80-92
Number of pages13
JournalActa reumatologica portuguesa
Volume2018
Issue number2
Publication statusPublished - Apr 2018

Keywords

  • Clinical trial
  • Dactylitis
  • Psoriatic arthritis
  • Treatment algorithm

Fingerprint Dive into the research topics of 'The GO-DACT protocol: A multicentre, randomized, double-blind, parallel-group study to compare the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy, in improving dactylitis and enthesitis, in MTX-naïve psoriatic arthritis patients'. Together they form a unique fingerprint.

Cite this